Therefore, one of our future goals is to identify the potential metabolism targets in a defined genetic and phenotypic context, for example, to identify the most important enzyme or metabolic intermediate in the most crucial metabolic pathway (e.g. glycolysis vs. TCA cycle vs. glutaminolysis, etc.)in lung adenocarcinoma harboring KRAS mutation, and determine how concomitant genetic alterations such as LKB1 inactivation modify the metabolic targets. The gene discussed is KRAS; the disease is lung adenocarcinoma.